Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Odyssey Therapeutics Announces $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases
_↗ odysseytx.com
News Image

Odyssey Therapeuticsa clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases, announced the successful completion of a $213 million Series D financing round. The funding will be used to advance the company's portfolio of clinical and preclinical medicines, all of which are designed to precisely target the underlying causes of complex autoimmune diseases. The financing round saw participation from all of Odyssey's existing investors and welcomed several new investors, including Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners.

In addition to the new funding, the company announced several new appointments to its Board of Directors. The new members include Shelley Chu from Lightspeed Ventures, Paulina Hill from Sanofi Ventures, Nan Li from Dimension Capital, Carolyn Ng from TPG Life Sciences Innovations, and Ksenija Pavletic from Jeito Capital. According to Odyssey's CEO and Founder, Gary D. Glick, Ph.D., the funding and the new board members signify the company's commitment to translating their scientific research into tangible benefits for patients. Jeff Leiden, M.D., Ph.D., Chairman of the Odyssey Board, also expressed his enthusiasm for the new investors and board members, stating that their involvement is a testament to the important medicines the company is working to discover.

Since its establishment in 2021, Odyssey Therapeutics has built a robust drug discovery and development infrastructure. The company has successfully moved an internally discovered program from its initial concept through various clinical milestones and has identified multiple development candidates. It has also forged collaborations with prominent pharmaceutical and biotech companies. Odyssey's mission is to transform the standard of care for patients with autoimmune and inflammatory diseases by creating medicines that offer a precise and effective approach to treating the conditions. Through its team of expert "drug hunters" and its comprehensive suite of tools, the company aims to develop product candidates that have the potential to bring about long-lasting relief for patients suffering from various inflammatory diseases with a high unmet need.

Log In
Sign Up